ViroCell Biologics Partners with U.S. Cancer Center for Gene Therapy Development

• ViroCell Biologics signs a five-year Master Services Agreement (MSA) with a prominent U.S. NCI-designated cancer center.

• The agreement provides access to ViroCell’s pre-clinical and clinical viral vector services to accelerate gene-modified cell therapies.

ViroCell Biologics, a cell and gene therapy contract development and manufacturing organization (CDMO), has entered into a five-year Master Services Agreement (MSA) with a prominent U.S. NCI-designated cancer center. This agreement will enable the cancer center to utilize ViroCell’s comprehensive range of pre-clinical and clinical viral vector services to expedite the development of novel gene-modified cell therapies.

The services provided under the MSA include viral vector design, MicroBatch and pre-clinical batch manufacturing, process development, global plasmid sourcing, GMP manufacturing, expedited quality control release testing, regulatory filing support, and in-house Qualified Person (QP) batch review and approval for global clinical trials.

This agreement follows the successful GMP manufacture of a lentivirus vector by ViroCell for the cancer center, which was used in the clinical evaluation of a novel engineered T cell receptor (TCR) therapy for various cancers. The vector was delivered for clinical use in less than five months from the start of GMP manufacture.

John W. Hadden II, CEO at ViroCell, stated, “We are delighted to have signed this Master Services Agreement with one of the world’s premier cancer research centers. It further underscores our ability to provide highly specialised GMP viral vector manufacturing services to cutting-edge research groups both in academia and industry as they translate their science into next-generation cell and gene therapies. We look forward to working closely with the scientists at this prestigious institution, as they commence exciting new cancer drug development programs.”